[go: up one dir, main page]

MX2007004025A - Uso de derivados del acido nordihidroguaiaretico en el tratamiento de cancer e infecciones microbial y viral resistente a farmacos._. - Google Patents

Uso de derivados del acido nordihidroguaiaretico en el tratamiento de cancer e infecciones microbial y viral resistente a farmacos._.

Info

Publication number
MX2007004025A
MX2007004025A MX2007004025A MX2007004025A MX2007004025A MX 2007004025 A MX2007004025 A MX 2007004025A MX 2007004025 A MX2007004025 A MX 2007004025A MX 2007004025 A MX2007004025 A MX 2007004025A MX 2007004025 A MX2007004025 A MX 2007004025A
Authority
MX
Mexico
Prior art keywords
resistant cancer
drug resistant
viral
nordihydroguaiaretic acid
treatment
Prior art date
Application number
MX2007004025A
Other languages
English (en)
Inventor
David E Mold
Yuan C Lee
Chih-Chuan Chuang
Ru Chih C Huang
Jih-Ru Hwu
Ming-Hua Hsu
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of MX2007004025A publication Critical patent/MX2007004025A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen composiciones y metodos para utilizar derivados del acido nordihidroguaiaretico (NDGA) para prevenir la expresion del gen MDR-1 y la sintesis de la proteina PgP o invertir la resistencia a farmacos multiples en celulas, y para usar derivados de NDGA en combinacion con agentes quimioterapeuticos adicionales para tratar el cancer e infecciones resistentes a farmacos.
MX2007004025A 2004-10-06 2005-10-06 Uso de derivados del acido nordihidroguaiaretico en el tratamiento de cancer e infecciones microbial y viral resistente a farmacos._. MX2007004025A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61611404P 2004-10-06 2004-10-06
PCT/US2005/035795 WO2006041902A2 (en) 2004-10-06 2005-10-06 Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection

Publications (1)

Publication Number Publication Date
MX2007004025A true MX2007004025A (es) 2007-06-11

Family

ID=36148866

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004025A MX2007004025A (es) 2004-10-06 2005-10-06 Uso de derivados del acido nordihidroguaiaretico en el tratamiento de cancer e infecciones microbial y viral resistente a farmacos._.

Country Status (8)

Country Link
US (1) US20080207532A1 (es)
EP (1) EP1848418A4 (es)
JP (1) JP2008520548A (es)
CN (1) CN101437505A (es)
AU (1) AU2005294432A1 (es)
CA (1) CA2583336A1 (es)
MX (1) MX2007004025A (es)
WO (1) WO2006041902A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2057265B1 (en) * 2006-08-28 2016-03-23 The Ohio State University Research Foundation Compositions for reducing cell adhesion to bubbles
ES2476249T3 (es) * 2006-10-02 2014-07-14 Erimos Pharmaceuticals Llc Derivados del NDGA tetrasustituidos por medio de enlaces éter y enlaces carbamatos y sus síntesis y usos farmacéuticos
EP2550976A3 (en) 2007-03-14 2013-04-03 Bionsil S.r.l. Modulator compounds of the drug resistance in epithelial tumour cells
US9149526B2 (en) 2008-01-08 2015-10-06 The Johns Hopkins University Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with metabolic modulators
US20100093872A1 (en) * 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
MX2011004824A (es) * 2008-11-07 2012-01-12 Triact Therapeutics Inc Uso de derivados de butano catecólico en terapia contra el cáncer.
ES2525833T3 (es) * 2010-02-22 2014-12-30 The Johns Hopkins University Supresión del crecimiento del cáncer y la metástasis mediante el uso de derivados de ácido nordihidroguayarético con 7-hidroxiestaurosporina
CA2832860A1 (en) * 2011-04-21 2012-10-26 Children's Hospital Medical Center Therapy for leukemia
US10342767B2 (en) 2011-04-21 2019-07-09 Children's Hospital Medical Center Therapy for kinase-dependent malignancies
US9084779B2 (en) 2011-05-31 2015-07-21 The Johns Hopkins University Conjugates of nitroimidazoles and their use as chemotherapeutic agents
SG11201404542TA (en) * 2012-02-03 2014-10-30 Univ Johns Hopkins Compositions comprising ndga derivatives and sorafenib and their use in treatment of cancer
AU2014223548A1 (en) * 2013-02-26 2015-10-15 Triact Therapeutics, Inc. Cancer therapy
GB201307989D0 (en) * 2013-05-02 2013-06-12 Helperby Therapeutics Ltd Novel combinations and use
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy
CN105902526A (zh) * 2016-05-06 2016-08-31 兰州大学 马索罗酚在制备治疗包虫病的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR890700023A (ko) * 1986-11-19 1989-03-02 케맥스 파마슈우티칼스 인코포레이티드 리폭시게나제 저해제
US5409690A (en) * 1993-06-23 1995-04-25 Chemex Pharmaceuticals, Inc. Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N
WO2006014669A2 (en) * 2004-07-20 2006-02-09 Erimos Pharmaceuticals Llc Methods and compositions for treatment of intraepithelial neoplasia

Also Published As

Publication number Publication date
JP2008520548A (ja) 2008-06-19
EP1848418A4 (en) 2010-09-08
WO2006041902A2 (en) 2006-04-20
CN101437505A (zh) 2009-05-20
AU2005294432A1 (en) 2006-04-20
WO2006041902A3 (en) 2009-04-16
CA2583336A1 (en) 2006-04-20
EP1848418A2 (en) 2007-10-31
US20080207532A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
MX2007004025A (es) Uso de derivados del acido nordihidroguaiaretico en el tratamiento de cancer e infecciones microbial y viral resistente a farmacos._.
MX2007012817A (es) Eliminacion de poblacion celular heterogenea o mezclada en tumores.
SG166093A1 (en) Inhibitors of brutonæs tyrosine kinase
DE602004017194D1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
NZ543661A (en) Pyrazolo-quinazoline derivatives having antitumor activity and process for their preparation
TR201903587T4 (tr) Telomeraz aktivitesinin artırılması için bileşimler.
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
MX272108B (es) Heterociclos sustituidos.
ATE433459T1 (de) Desoxo-nonadepsipeptide
NO20075508L (no) Stannsoporfinpreparater og administrering
HK1110518A (en) Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection

Legal Events

Date Code Title Description
FA Abandonment or withdrawal